Miracalus Taceedo 120 mg Injection

Get a Price/Quote

MOQ : 10 Pieces

Miracalus Taceedo 120 mg Injection Specification

Dosage Form
Injection

Salt Composition
Docetaxel 120 mg

Indication
Treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head & neck cancer

Feature

Ingredients
Docetaxel Trihydrate, Excipients

Application
Intravenous use in oncology

Physical Color/Texture
Clear or slightly yellowish solution

Storage Instructions
Store below 25C, protect from light

Shelf Life
24 months

Strength
120 mg per vial

ATC Code
L01CD02

Pharmacological Class
Taxane derivative

Packaging Type
Single-use vial

Market Availability
International (including Canada, EU, UK, USA, Australia)

Prescription Required
Yes

Route of Administration
Intravenous

Brand Name
Miracalus Taceedo 120 mg Injection

Miracalus Taceedo 120 mg Injection About

Capitalise on the value offered by the new release of Miracalus Taceedo 120 mg Injection-a famed antineoplastic chemotherapy medication known for its imposing efficacy. This breathtaking advancement features Docetaxel 120 mg per vial, specifically designed for intravenous administration, and is available as a single-use vial. Indicated for the treatment of breast, non-small cell lung, prostate, gastric, and head & neck cancers, it is internationally available including in Canada, EU, UK, USA, and Australia. Prescription is required. Manufactured and supplied from India, Miracalus Taceedo showcases a clear or slightly yellowish solution with a shelf life of 24 months.

Miracalus Taceedo 120 mg Injection: Clinical Application and Features

Miracalus Taceedo 120 mg Injection is applied intravenously in oncology settings, delivering targeted therapy for various solid tumors. Its specific use covers breast, lung, prostate, gastric, and head & neck cancers, making it a versatile solution in cancer management. This injection, formulated as a clear or slightly yellowish solution, features highly potent Docetaxel Trihydrate and specialised excipients, ensuring high-grade material quality and consistent therapeutic outcomes in hospital and clinical environments.

Supply Capacity, Certifications & Export Markets for Miracalus Taceedo 120 mg

Our supply abilities are geared to meet large-scale demand, supporting hospital expenditure with cost-efficient procurement models. Miracalus Taceedo 120 mg Injection carries internationally recognised certifications, assuring superior standards. We ensure seamless global distribution with robust transport services and express shipping options, especially to markets across Canada, EU, UK, USA, and Australia. This cost-effective approach enables convenient access for major oncology centers and clinics worldwide.

FAQ's of Miracalus Taceedo 120 mg Injection:

Q: How is Miracalus Taceedo 120 mg Injection administered?

A: Miracalus Taceedo 120 mg Injection is administered by intravenous infusion under the supervision of a healthcare professional experienced in chemotherapy.

Q: What cancers are treated with Miracalus Taceedo 120 mg Injection?

A: This medication is indicated for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head & neck cancers.

Q: When should Miracalus Taceedo 120 mg Injection be used?

A: Miracalus Taceedo 120 mg Injection should be used when prescribed by an oncologist for specific types of cancers requiring a taxane-based chemotherapy regimen.

Q: Where is Miracalus Taceedo 120 mg Injection available?

A: Miracalus Taceedo 120 mg Injection is available internationally, including markets in Canada, the EU, UK, USA, and Australia.

Q: What is the benefit of using Miracalus Taceedo 120 mg Injection in cancer therapy?

A: It delivers a proven taxane derivative, Docetaxel, ensuring effective management of numerous solid tumors with a well-established safety and efficacy profile.